FDA OKs Eravacycline for Complicated Intra-Abdominal Infections


Officials with the US Food and Drug Administration (FDA) have approved eravacycline, (Xerava, Tetraphase Pharmaceuticals) for the treatment of complicated intra-abdominal infection (cIAI) in adults 18 years and older.

Eravacycline is a tetracycline-class antibacterial injection that has demonstrated potent activity against multidrug-resistant pathogens. In clinical trials, eravacycline was well tolerated, produced favorable results in curing patients with cIAIs, and demonstrated non-inferiority to ertapenem and meropenem.

The drug does not have a dose adjustment requirement when given to patients with renal impairment and it may be given to patients with penicillin allergies, according to a statement issued by Tetraphase.

“[Eravacycline is] a fluorocycline-type tetracycline. This drug is active against resistant Enterobacteriaceae and some gram-positive organisms as well,” explained Jason Gallagher, PharmD, clinical professor, Temple University School of Pharmacy, editor-in-chief of Pharmacy Times' sister publication Contagion®, in a recent interview. “It’s fairly broad in its spectrum; it does not have activity against Pseudomonas similar to tigecycline or the other tetracyclines.”

For more on the interview with Dr. Gallagher, visit Contagion.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.